Problem or solution: The strange story of glucagon

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Diseases

Background:

• Obesity affects 13% of adults globally, and over 400 million have diabetes, imposing significant health and economic burdens.
• Hyperglucagonemia is a hallmark of diabetes, suggesting glucagon's role in its development.
• Glucagon also increases energy expenditure, presenting a potential therapeutic target for obesity.

Purpose of the Study:

• To review the conflicting physiological roles of glucagon.
• To discuss pharmacological strategies for harnessing glucagon's effects.
• To explore novel peptide-based treatments for obesity and diabetes.

Main Methods:

• Review of existing literature on glucagon physiology and pharmacology.
• Analysis of ongoing clinical trials for glucagon-targeting therapies.
• Discussion of peptide design principles for dual incretin and glucagon receptor agonism.

Main Results:

• Glucagon contributes to hyperglycemia in diabetes but can increase energy expenditure.
• Drugs blocking glucagon are in clinical trials for type 2 diabetes.
• Novel peptides aim to activate glucagon receptors while providing incretin effects.

Conclusions:

• Glucagon presents a complex therapeutic target due to its opposing roles in diabetes and energy balance.
• Pharmacological manipulation of glucagon offers a promising avenue for treating both obesity and diabetes.
• Dual-action peptides represent a potential strategy for managing these interconnected metabolic disorders.